In this multicenter retrospective study of 150 pediatric patients supported with the Impella device, 89.3% achieved positive clinical outcomes despite a 28% adverse event rate. Findings suggest a potential role for Impella in managing refractory advanced heart failure in children, particularly those with cardiomyopathy, transplant graft dysfunction, or congenital heart disease.
The use of VADs in pediatric restrictive and hypertrophic cardiomyopathy is rare, but this ACTION multi-center registry analysis highlights that support is feasible, particularly in children with RCM. While the majority of patients were successfully bridged to transplant, outcomes were poorer in HCM patients, especially those requiring BiVAD support.
CHD patients are more likely in extremis at VAD implantation and experience higher rates of adverse events and worse survival compared to those with non-CHD. Timely referral for patients with CHD experiencing worsening heart failure and a proactive approach to VAD implantation has the potential to improve outcomes for this vulnerable cohort.
Abstract We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative
Friday, April 12th 11:00–11:10 AM Timing of Stroke in Children Supported by Ventricular Assist Devices – An ACTION Registry Report Muhammad Farrukh Shezad, et al.
The HeartWare ventricular assist device (HVAD) was discontinued in July 2021. The study aims to describe the impact the discontinuation the HVAD had on pediatric ventricular assist device (VAD) utilization and outcomes.
Happy New Year! We hope you enjoyed the Holiday Season and are energized for a new year! We wrapped 2023 with the launch of several exciting projects, such as the HeartMate 3TM Discharge Bundle and Heart Healthy Video Series, we continued access to the Berlin Heart Active Driver under the extended trial, and we published new ACTION research. Looking ahead this year we have been meeting individually with all ACTION sites to ensure successful engagement in ACTION and highlight membership benefits for each center. We are excited to expand quality improvement, education, research, and best practice initiatives across the network, as well as engage with Global centers and increase advocacy efforts in the pediatric heart failure space. Reach out with any new ideas for the year ahead. Thank you for your continued efforts!
The Pulse — January 2024 Read More »
Patients with Fontan failure are high-risk candidates for heart transplantation and other advanced therapies. Understanding the outcomes following initial heart failure consultation can help define appropriate timing of referral for advanced heart failure care.
Outcomes after initial heart failure consultation in Fontan patients Read More »
ACTION set forth to report current outcomes in patients supported with the HeartMate 3 ventricular assist device in a multicenter learning network.
Expanding Use of the HeartMate 3 VAD in Pediatric and Adult Patients within ACTION Read More »
Ventricular assist device (VAD) options vary for children in different weight groups. This study evaluates contemporary device usage and outcomes for children based on weight.
"*" indicates required fields
Copyright © 2024 Advanced Cardiac Therapies Improving Outcomes Network
